Tilos Therapeutics

Tilos Therapeutics is a product-focused company developing anti-LAP antibodies for the treatment of cancer, with additional early efforts in fibrosis and autoimmune diseases. Tilos was built on decades of work by its scientific founders, who have elucidated the role of LAP-expressing cells in immune regulation, enabling the rapid advancement of anti-LAP antibodies into clinical development. Founded in 2016, Tilos is headquartered in Cambridge, Massachusetts.